The Singular Centre for Research in Molecular Medicine and Chronic Diseases (CiMUS) was created by agreement of the Governing Council of the University of Santiago de Compostela on 17 February 2010, bringing together USC biomedicine teams selected for their competitive quality. CiMUS has experienced exponential growth in the last 10 years, with a fundraising of more than 100 million euros, 2130 publications in journals such as Nature, Science, Cell, etc., 31 patents, the creation of 7 companies in the field of biomedicine, and the creation of 7 new companies. 31 patents, the creation of 7 companies based on the centre's results, and an ERIC EU-OPENSCREEN node classified as one of the 8 with the highest research capacities. In 2022, it was the centre in Galicia that attracted the most public projects funded by the AEI and also private projects from institutions such as the AECC, European Foundation for the Study of Diabetes, Fundación la Caixa, and others.
CiMUS has CIGUS recognition from the Xunta de Galicia, which accredits the quality and impact of its research.
CiMUS is a member of the network of singular research centres with a new model of scientific organization, which constitutes one of the R&D strategic pillars of the CAMPUS VIDA project (Campus of International Excellence, MEC-MICINN, 2009).
Mission:
The mission of CiMUS is to promote research of excellence and the advancement of knowledge in the molecular basis and therapy in chronic diseases with socio-health relevance, focused on population ageing, working at the frontier between biomedical research and clinical application, with the aim of developing Precision Medicine. With this, CiMUS will promote important social benefits in public health and healthy ageing, socio-economic prosperity through technology transfer, as well as training and recruitment of high-level scientists for our environment.
Vision:
The vision of CiMUS is to consolidate itself as a centre of international excellence in the field of biomedical research and, particularly, chronic diseases of high socio-health relevance.
Structure:
In order to achieve our intended objective, CiMUS is structured into two programmes that interact with each other. A first programme investigating the molecular mechanisms of chronic diseases (metabolic/obesity, cardiovascular, neurological and cancer), the "Molecular Medicine Programme". And a second programme, the "Translational Integrative Programme", which researches new drugs, new therapeutic strategies and genomics (drug screening, nanodelivery, genomic and teragnostic medicine), promoting the translation of the programme and CiMUS as a whole towards Precision Medicine.
Our centre:
